Oxidoreductases (1. ) (e.g., Catalase, Dehydrogenases, Reductases, Etc.) Patents (Class 424/94.4)
  • Patent number: 11873519
    Abstract: A composition and method for reversing or preventing age-related metabolic and tissue degenerative changes in individuals. The method includes administering, orally, an effective amount of a first composition having methioninase enzyme. The method further includes administering, by a route other than the oral route, such as a parenteral route, an effective amount of a second composition having methioninase enzyme. The method further includes the steps of orally and/or parentally administering pyridoxal-L-phosphate.
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: January 16, 2024
    Inventors: Qinghong Han, Robert M Hoffman
  • Patent number: 11825846
    Abstract: This disclosure provides a method of disinfecting a surface within an area, comprising the steps of: a) dispersing into the area a multiplicity of droplets of a first aqueous composition comprising a first iodine reactant compound that is either a peroxide compound or an iodine salt compound: b) allowing sufficient time for the first aqueous composition to distribute throughout the area, and to deposit and coalesce into a layer upon the surface: c) dispersing into the area a multiplicity of droplets of a second aqueous composition comprising a second iodine reactant compound that is the other of the first iodine reactant compound, and: d) again allowing sufficient time for the droplets of the second aqueous composition to deposit onto the coalesced layer of the first aqueous composition, thereby forming iodine and other iodine biocides in situ and disinfecting the surface.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: November 28, 2023
    Assignee: MARKESBERY BLUE PEARL LLC
    Inventor: Eugene Joseph Pancheri
  • Patent number: 11781119
    Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: October 10, 2023
    Assignee: Horizon Therapeutics USA, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Patent number: 11723958
    Abstract: The present disclosure provides compositions of microparticles and uses thereof for removing toxic or undesirable molecules from an environment, e.g. the blood of a subject. The microparticles can be liposomes. In one embodiment, the aqueous phase of the liposomes contains (i) a system of generating NAD+ from NADH, and (ii) one or more enzymes that are involved in one or more NAD+-dependent reactions that remove the toxic or undesirable molecules from the environment. In one embodiment, the liposomes contain NADH oxidase, alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) to remove ethanol from the blood of a subject.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: August 15, 2023
    Assignee: SYNLIFE, INC.
    Inventors: Felix Moser, David Benjamin
  • Patent number: 11717557
    Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: August 8, 2023
    Assignees: Lubris LLC, Rhode Island Hospital
    Inventors: Gregory D. Jay, Benjamin D. Sullivan, Tannin Avery Schmidt, Khaled Elsaid, Edward R. Truitt, Roman Krawetz, Jawed Fareed, Joanna Szmydynger-Chodobska, Adam Chodobski
  • Patent number: 11712429
    Abstract: In various embodiments, the present invention provides pharmaceutical compositions and methods for treating cardiovascular-related disease.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: August 1, 2023
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Jonathan Rowe
  • Patent number: 11712428
    Abstract: In various embodiments, the present invention provides pharmaceutical compositions and methods for treating cardiovascular-related disease.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: August 1, 2023
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Jonathan Rowe
  • Patent number: 11696891
    Abstract: The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono ?-lactone, wherein the glucono ?-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono ?-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: July 11, 2023
    Assignee: Gedea Biotech AB
    Inventors: Ulf Ellervik, Olov Sterner, Helena Strevens, Sophie Manner
  • Patent number: 11679178
    Abstract: The present invention relates to enhancing mechanical properties of tissue such as collagenous or collagen-containing or elastin-containing tissue (e.g., tendons, ligaments, and cartilage) and treating related musculoskeletal and non-musculoskeletal conditions or injuries.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: June 20, 2023
    Assignee: University of Rochester
    Inventor: Catherine K. Kuo
  • Patent number: 11647766
    Abstract: Aseptic beverage products are prepared by mixing beverage ingredients together. The beverage ingredients include a protein source, such as a milk protein concentrate, and at least one buffering agent, with the at least one buffering agent including baking soda. Preferably, the at least one buffering agent further includes lemon juice concentrate. The pH of the beverage ingredients is adjusted to a level between 6.7 and 7.0 using the at least one buffering agent. The beverage ingredients are then heated to at least 139° C., and the at least one buffering agent prevents precipitation of the protein source during heating. Afterwards, the beverage ingredients are packaged as a plurality of aseptic beverage products.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: May 16, 2023
    Assignee: General Mills, Inc.
    Inventors: Michele Wolf, Erika Smith, Jon Firebaugh
  • Patent number: 11612584
    Abstract: The present invention concerns a pharmaceutical composition comprising a compound of Formula I for use in the treatment and/or prevention of microbial infections. Furthermore, the present invention concerns a method for prevention and/or reduction of biofilm formation.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 28, 2023
    Assignee: Gedea Biotech AB
    Inventors: Ulf Ellervik, Olov Sterner, Helena Strevens, Sophie Manner
  • Patent number: 11583574
    Abstract: An oral product comprising nano-sized, heat tolerable, shelf stable peptides and enzymes. Once the peptides and enzymes are inside the body of a user, they dimerize the nucleic acids of viruses, bacteria and fungi. Thus, the peptides and enzymes are capable of inactivating the genome of pathogens, including without limitation, SARS-CoV-2 and Influenza A/CA/04/2009 (H1N1) virus.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: February 21, 2023
    Inventor: Mitchell Lynn Tate
  • Patent number: 11521745
    Abstract: The invention proposes a new method for monitoring a health event in a mammal, comprising detecting at least one abnormal value within a series of values related to at least one biomarker, based on appropriate Z-scores.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: December 6, 2022
    Inventors: Geoffroy Berthelot, Jérôme Dedecker, Guillaume Sauliere
  • Patent number: 11517014
    Abstract: The present invention provides compositions and methods for reducing microbial contamination or infection in plants, animals, fabrics, and products therefrom. The present invention also provides compositions and methods for reducing human infections. In particular, it provides solid magnetic nanoparticles comprising bacteriostatic, bactericidal, fungistatic, or fungicidal enzymes in one component, and substrates for the enzymes in another component. The compositions are dormant and become active upon exposure to hydration and oxygen.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: December 6, 2022
    Assignee: ZYMtronix, Inc.
    Inventor: Stephane Corgie
  • Patent number: 11491117
    Abstract: The disclosure pertains to a compound of formula (I), one of its pharmaceutically acceptable salts, or a composition comprising thereof, for use in the prevention or treatment of glucose intolerance related conditions, insulin deficit related conditions, nonalcoholic fatty liver disease and/or obesity.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: November 8, 2022
    Assignees: SORBONNE UNIVERSITÉ, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, KYOTO UNIVERSITY
    Inventors: Dominique Gauguier, Fumihiko Matsuda, François Brial
  • Patent number: 11459363
    Abstract: A Transactivator of Transcription-frataxin (TAT-FXN) fusion polypeptide useful in treating subjects diagnosed with Friedreich's Ataxia, hypertrophic cardiomyopathy, or both are disclosed, as are related methods of treatment and pharmaceutical compositions.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: October 4, 2022
    Assignee: The Trustees of Indiana University
    Inventor: Ronald Mark Payne
  • Patent number: 11453914
    Abstract: Provided are methods for detecting or diagnosing a traumatic brain injury or TBI by detecting concentration levels miRNAs associated with TBI in saliva. Methods for controlled and normalized comparisons of salivary miRNA concentration levels are further provided. Assay kits comprising salivary miRNAs, probes and/or primers for detecting salivary miRNAs are also provided.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: September 27, 2022
    Assignees: QUADRANT BIOSCIENCES INC., THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, PENN STATE RESEARCH FOUNDATION
    Inventors: Steven D. Hicks, Frank A. Middleton, Richard Uhlig
  • Patent number: 11389412
    Abstract: Provided herein are solid form water soluble curcuminoid compositions, including a curcuminoid; and a solubilization matrix, wherein the solubilization matrix is selected from one or more of the following: (i) chlorophyllin (CHL); (ii) green tea extract; (iii) epigallocatechin gallate (EGCG); (iv) Rutin; and (v) an aromatic amino acid. Alternatively, the solubilization matrix may include methylsulfonylmethane (MSM). Also provided herein are methods for producing curcuminoid compositions.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: July 19, 2022
    Assignee: InovoBiologic Inc.
    Inventors: Chuck Chang, Sangho Lee, Youngse Jang, Yoon Seok Roh
  • Patent number: 11389514
    Abstract: Compositions comprising a combination of myeloperoxidase and a peroxide-producing oxidase and methods of using the compositions to inactivate gram negative bacterial lipopolysaccharides and lipid A endotoxin are provided.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: July 19, 2022
    Assignee: EXOXEMIS, INC.
    Inventor: Robert C. Allen
  • Patent number: 11371036
    Abstract: A composition and method for lowing serum and plasma levels of methionine by oral administration. The composition includes a recombinant methioninase enzyme and a cofactor (pyridoxal-L-phosphate). Methods of use describe methods for treatment of cancer, including malignant melanoma, by oral administration of the methioninase composition. Methods for chronic suppressive therapy of melanoma and other cancers are described. Because reduction of plasma methionine levels is effective in treating other conditions, including diabetes and conditions associated with aging, the use of the methods described herein includes treatment of these and other conditions.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: June 28, 2022
    Inventors: Qinghong Han, Robert M Hoffman
  • Patent number: 11364219
    Abstract: The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of several chronic diseases. Thus characterization of new post-biotic compounds inducing beneficial changes on host-microbiota interactions may be highly desirable. The inventors showed that Nlrp6 diurnally coordinates cyclical adaptation of the gut microbiota diversity to epithelial plasticity in response to a treatment with a Csnk2 inhibitor. The invention therefore relates to an inhibitor of Csnk2, for use in the treatment of microbiome dysregulations notably associated with circadian clock disruption. Said inhibitor may be selected among chemically synthesized or natural selective Csnk2 inhibitors such as flavones.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: June 21, 2022
    Assignees: INSERM (INSTITUT NATION DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LILLE, INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CRNS—
    Inventor: Mathias Chamaillard
  • Patent number: 11345899
    Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: May 31, 2022
    Assignee: HORIZON THERAPEUTICS USA, INC.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Patent number: 11311566
    Abstract: The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: April 26, 2022
    Assignee: Innovation Hammer, LLC
    Inventor: Arthur M. Nonomura
  • Patent number: 11311567
    Abstract: The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: April 26, 2022
    Assignee: Innovation Hammer, LLC
    Inventor: Arthur M. Nonomura
  • Patent number: 11261222
    Abstract: A transdermal peptide with a nuclear localization ability and having an amino acid sequence as shown in SEQ ID NO: 1 is disclosed. A fusion protein including a macromolecular protein with one end being linked to the transdermal peptide is also disclosed. The transdermal peptide can be used in the preparation of a medicament or a transdermal preparation for treating skin diseases. A medicament for treating a skin disease includes the transdermal peptide and a pharmaceutically acceptable excipient. The transdermal peptide enters the cells autonomously to locate in the nuclei, and can penetrate through the stratum corneum of the skin into cells in the dermis. The peptide is conveniently synthesized artificially and suitable for transdermal administration, and has a therapeutic potential via transdermal administration by carrying a drug for treating skin diseases.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: March 1, 2022
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Shuyu Zhang, Jianping Cao, Daojiang Yu, Wei Zhu
  • Patent number: 11116809
    Abstract: The invention provides compositions comprising milk thistle, dandelion root, and/or one or more antioxidant amino acids (e.g., n-acetyl L-cysteine) for the treatment and prevention of liver disease (hepatic insufficiency) in a mammal (e.g., equine). The composition may further comprise chitosan and/or additional components that prevent or treat liver disease or hepatic insufficiency (e.g., inulin, prebiotics).
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 14, 2021
    Inventors: Scott P. Noel, John Kirk Shumpert, Alex Greene, William Brian Austin
  • Patent number: 11045403
    Abstract: Disclosed is a composition and method for its use that includes Magnolia bark extract, Vitis vinifera extract, tocopherol or tocopherol acetate, and hydrogenated lecithin, lecithin, or dextrin.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: June 29, 2021
    Assignee: Belaj Innovations LLC
    Inventors: Jim Faller, David Gan, Michelle Hines, Lisa Mangos
  • Patent number: 11039999
    Abstract: Compositions comprising vitamin E, vitamin C, and white tea extract for treating cutaneous signs of aging are disclosed. The compositions reduce signs of wrinkles and improve other skin conditions, such as increased skin elasticity and skin softness. Moreover, the prevention or treatment of unhealthy skin, such as aged skin or skin overexposed to sunlight, may advantageously be accomplished by the administration of the compositions of the present invention The compositions includes the combination of a number of different components, which interact to provide the desired improvements to the skin Further advantageous ingredients of the compositions may comprise, naturally occurring antioxidants extracted from e g grape seeds and tomato, an extract comprising glycosaminoglycans, a transition metal component in an amount effective to bind collagen and elastic fibers and thicken skin, and a catechin-based component present in an amount sufficient to inhibit the presence of anti-collagen enzyme in the skin.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: June 22, 2021
    Assignee: Ferrosan APS
    Inventors: Annebeth Siø Jensen, Annette Strarup Kristensen, Henrik Enghusen Poulsen, Jana Vicanova, Nico Smit
  • Patent number: 10993436
    Abstract: The present invention provides compositions and methods for reducing bacterial contamination or infection in plants, animals, fabrics, and products therefrom. The present invention also provides compositions and methods for reducing human infections and the emergence of antibiotic resistance. In particular, the invention provides magnetic nanoparticles comprising bactericidal or bacteriostatic enzymes in one component, substrates for the enzymes in a second component, and a bactericidal chemical agent that works in combination or synergistically with the enzymes. The compositions are dormant and become active upon exposure to hydration, oxygen, or mixing.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: May 4, 2021
    Assignee: ZYMtronix Catalytic Systems, Inc.
    Inventors: Stephane Cedric Corgie, Zachariah Robert Hansen
  • Patent number: 10946063
    Abstract: A fusion protein is described, comprising a first N-terminal signal peptide sequence, a second peptide sequence C-terminal to the signal peptide sequence, and a third peptide sequence C-terminal to the second peptide sequence; wherein one of the second peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence and the other is a hydrophilic peptide sequence. After translation the signal peptide is cleaved, leaving a fusion protein comprising the second peptide sequence and the third peptide sequence minus the signal peptide. Also described are nucleic acids and expression vectors encoding the fusion protein, cells comprising the nucleic acid or expression vector, as well as methods of treatment and uses of the fusion protein, nucleic acid, and expression vector. The fusion protein can be produced in vitro by culturing the cells of this invention under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: March 16, 2021
    Assignee: Welltat Ophthalmics Corporation
    Inventors: Tianci Luo, Jun Zhang
  • Patent number: 10947145
    Abstract: A method for improved anaerobic digestion is presented. The method includes mixing a volume of waste material with water to form a feedstock mixture. The volume of waste material includes an initial amount of biomass and the feedstock mixture includes methanogenic bacteria either naturally present in the waste material or introduced artificially. The method also includes introducing one or more promoter substances to the feedstock mixture. The one or more promoter substances are capable of modifying the methanogenic bacteria. Modifying includes stimulating novel enzyme production in the methanogenic bacteria.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: March 16, 2021
    Assignee: TOPSTONE VENTURES, LLC
    Inventor: Christopher J Barry
  • Patent number: 10874724
    Abstract: In some embodiments the present disclosure pertains to a method of activating an anti-tumor immune response for the treatment of a cancer. In some embodiments, such a method comprises detecting CD26 expression in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising adenosine deaminase. In some embodiments, the adenosine deaminase stimulates T cell proliferation and activates maturation of macrophages or dendritic cells. In some embodiments, the present disclosure pertains to a method for targeted reduction of adenosine or deoxyadenosine in a tumor microenvironment of a solid tumor.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: December 29, 2020
    Assignee: UNIVERSITY OF HOUSTON SYSTEM
    Inventors: Navin Varadarajan, Irfan Naseem Bandey
  • Patent number: 10864190
    Abstract: The present invention relates to the combination of an antiandrogen with a vitamin K antagonist or with a ?-glutamyl carboxylase inhibitor for use in the treatment or prevention of an androgen receptor positive cancer, such as prostate cancer, or a hyperactive androgen receptor signaling disease/disorder. The invention also relates to a vitamin K antagonist or a ?-glutamyl carboxylase inhibitor for use in resensitizing an antiandrogen-resistant prostate cancer to the treatment with an antiandrogen. The invention further provides a pharmaceutical composition comprising an antiandrogen, a vitamin K antagonist or a ?-glutamyl carboxylase inhibitor, and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: December 15, 2020
    Assignee: CEMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH
    Inventors: Stefan Kubicek, Marco Licciardello
  • Patent number: 10786524
    Abstract: The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: September 29, 2020
    Assignee: Innovation Hammer LLC
    Inventor: Arthur M. Nonomura
  • Patent number: 10761087
    Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 1, 2020
    Assignees: LINK GENOMICS, INC., ROHTO Pharmaceutical Co., Ltd.
    Inventors: Shinichiro Niwa, Dai Ogura, Hidemi Mizunuma, Yoko Arai, Takahiro Kurose, Yoshihiro Takai, Yoko Mitsuguchi, Mariyo Moriya
  • Patent number: 10709360
    Abstract: The disclosure concerns medical devices configured to utilize nitric oxide (NO) donor materials to release NO gas upon contact with moisture in order to mitigate bacterial proliferation, coagulation, or a combination thereof, at a site of a biosensor integrated within the medical device. A novel multi-lumen medical device is described, the device having a first lumen for containing the NO donor material and producing the NO gas, and having a second lumen for housing biosensor componentry. A channel between the first and second lumens serves to communicate NO gas from the first lumen to a sensor-volume of the biosensor.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: July 14, 2020
    Assignee: BIOCREDE INC.
    Inventors: Hao Chen, Alexander Wolf, Kevin Renehan
  • Patent number: 10702584
    Abstract: The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: July 7, 2020
    Assignee: BBS-BIOACTIVE BONE SUBSTITUTES OYJ
    Inventors: Hanna Tölli, Juha-Matti Närhi, Harri Lumme, Elli Birr, Oili Hietala, Mikko Viitanen, Merja Haikola, Pekka Jalovaara, Bo Kenneth Sandström
  • Patent number: 10668161
    Abstract: Methods for modifying therapeutic agents such as therapeutic biomolecules, such as proteins for improved oral, rectal or transmucosal delivery, as well as compositions made using such methods and methods of administering such compositions to a subject, are disclosed. Specifically, the therapeutic agents are conjugated to hyperbranched polymers (HBPs), such as hyperbranched polyglycerol (HPG). When such conjugates are administered orally to a subject, the HBP protects the therapeutic agent from the acid environment of the stomach and protease attack in the gastro-intestinal tract, while facilitating the absorption of the therapeutic agent in the higher pH environment of the intestines. The methods and compositions are useful for the improved administration of a variety of therapeutic agents to a subject.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: June 2, 2020
    Assignee: The Regents of the University of California
    Inventors: Yunfeng Lu, Juanjuan Du, Jie Li, Yang Liu
  • Patent number: 10668129
    Abstract: The present invention relates to the synergistic combination of the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 2, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Thierry Leveillard, John Flannery, Xin Mei, Leah Byrne, José-Alain Sahel, Emmanuelle Clerin-Lachapelle, Junwei Sun, Jean Bennett, Jeannette Bennicelli
  • Patent number: 10463772
    Abstract: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: November 5, 2019
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, Hui Liu, Patrick M. Hughes, Lon T. Spada, Alazar N. Ghebremeskel
  • Patent number: 10457942
    Abstract: Several embodiments relate to methods of repairing and/or regenerating damaged or diseased tissue comprising administering to the damaged or diseased tissues compositions comprising exosomes. In several embodiments, the exosomes comprise one or more microRNA that result in alterations in gene or protein expression, which in turn result in improved cell or tissue viability and/or function.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: October 29, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Eduardo Marbán, Ke Cheng, Ahmed Ibrahim
  • Patent number: 10441667
    Abstract: The invention relates to a composition for the detection of tooth demineralization. More specifically, the invention concerns a composition comprising a complex capable of producing an optical signal characteristic of the presence of free ions, the pharmaceutical uses of such a composition, and methods and a kit for the detection of active demineralization at tooth surfaces using such a composition.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: October 15, 2019
    Assignee: Calcivis Limited
    Inventors: Emma Perfect, Chris Longbottom
  • Patent number: 10408823
    Abstract: The present invention is directed to methods for improving assay specificity and performance in binding assays.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: September 10, 2019
    Assignee: Meso Scale Technologies, LLC.
    Inventors: Anahit Aghvanyan, Eli N. Glezer, John Kenten, George Sigal, Martin Stengelin, David Routenberg
  • Patent number: 10383921
    Abstract: Disclosed herein are compositions and methods for providing an antioxidant effect to a subject, e.g., modulating or otherwise improving oxidative stress pathways and/or neutralizing or reducing damaging reactive oxygen species (ROS).
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: August 20, 2019
    Assignees: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, COMPAGNIE GERVAIS DANONE
    Inventors: Wendy S. Garrett, Patrick Veiga, Sonia Arora Ballal, Johan van Hylckama Vlieg, Gaëlle Quéré, Peggy Garault
  • Patent number: 10266493
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: April 23, 2019
    Assignee: Ardea Biosciences, Inc.
    Inventors: Samedy Ouk, Esmir Gunic, Jean-Michel Vernier, Chixu Chen
  • Patent number: 10251408
    Abstract: The present invention provides a composition comprising a tea extract or a catechin and a citrus fruit extract or a flavanone or a glycoside thereof.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: April 9, 2019
    Assignee: Kyushu University, National University Corporation
    Inventor: Hirofumi Tachibana
  • Patent number: 10196625
    Abstract: Provided herein is a means for increasing protein retention in blood. The protein retention in blood is increased by forming a conjugate of a protein and chondroitin produced by a microorganism having chondroitin-producing capability and/or chondroitin synthesized with a chondroitin synthase.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: February 5, 2019
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Yoshihiro Takatsu, Masanobu Fukushima
  • Patent number: 10189008
    Abstract: The present invention relates to a water-absorbing composition comprising at least i) 89 to 99.89 wt % of at least one water-absorbing polymer; ii) 0.1 to 10 wt % of at least one oxidizing agent; iii) 0.01 to 1 wt % of at least one inhibitor to inhibit free-radical polymerizations; wherein the weight quantities are each based on the overall weight of the water-absorbing composition. The present invention also relates to a process for producing a water-absorbing composition, the water-absorbing composition obtainable by this process, a composite, a process for producing a composite, the composite obtainable by this process, chemical products such as foams, moldings, fibers, foils, films, cables, sealing materials, liquid-imbibing hygiene articles, carriers for plant and fungal growth regulators, packaging materials, soil additives or building products and also the use of a water-absorbing composition.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: January 29, 2019
    Assignee: Evonik Degussa GmbH
    Inventors: Laurent Wattebled, Jessica Pillat, Lisa Maus, Scott Smith, Jorg Harren
  • Patent number: 10183026
    Abstract: A method of increasing abundance of hematopoietic stem cells and progenitor cells and an adjuvant method of radiotherapy based treatment for radioprotection of the subject against ?-radiation toxicity and/or IR-induced death of cancer cells involving pharmaceutically effective dosages of chlorophyllin or a pharmaceutically acceptable salt thereof. The advancement is directed to selectively protect normal hematopoietic stem cells and/or sensitizes radio-resistant cancer cells to gamma radiation thereby lowering the risk of normal tissue radiation toxicity. The effective dose of the CHL formulation synergistically improves the outcome of radiotherapy for cancer when administered to the subject prior the radiotherapy for treating cancer. Also disclosed is kit having chlorophyllin containing therapeutic preparation for treating indications selected from reduction in hematopoietic stem cells and progenitor cells (HSPCs) and/or protection against whole body irradiation induced mortality.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: January 22, 2019
    Assignee: THE SECRETARY, DEPARTMENT OF ATOMIC ENERGY
    Inventors: Deepak Sharma, Santosh Kumar Sandur, Rahul Checker, Raghavendra Shridhar Patwardhan, Vikram Prakash Gota, Jayakumar Sundarraj, Preetha Sasi, Subrata Chattopadhyay
  • Patent number: 10123965
    Abstract: The present disclosure provides formulations, methods and devices for periorbital skin rejuvenation. A periorbital skin serum in accordance with the present disclosure comprises squalane (sugarcane derived), vitamin E (tocopheryl acetate), vitamin C (tetrahexyldecyl ascorbate), and ubiquinone (coenzyme Q10, oxidized form).
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: November 13, 2018
    Assignee: YOUNIQUE, LLC
    Inventor: Mukhtar Siddiqui